Curvebeam Ai Ltd. · ASX:CVB
Curvebeam Ai — Q1 FY26 Earnings Presentation
10 slides from Curvebeam Ai's earnings presentation, Oct 30, 2025
Slide 1: Q1 FY26 Quarterly Company Call
Q1 FY26 QUARTERLY COMPANY CALL 30 October 2025
Slide 2: FY26 Q1 Key Activities
FY26 Q1 KEY ACTIVITIES • Purchase orders (POs) for four (4) devices in Q1 FY26, three (3) of which were HiRise™ – growth of 33.3% over the prior corresponding period. • Placement completed to raise A$6.5m from institutional & sophisticated investors. • Increased engagement from the vendor of a major
Slide 3: China Strategy: Targeted Strategic Benefits
CHINA STRATEGY TA R G E T E D S T R AT E G I C B E N E F I T S ü Capital injection with reduced dilution – A$10m at 40.5 cents ü Rapid entry into one of the world’s largest & fastest-growing medical device markets ü China will be initially supplied US manufactured HiRise – short term boost to compan
Slide 4: China Agreements
CHINA AGREEMENTS Key terms Share Subscription Agreement • The Partner will make an equity investment of up to A$10 million in CVB as follows: & Voluntary Escrow Deed • Execution of license agreements A$4 million milestone payment. • HiRiseTM sold generating ~A$4.6 million in sales – A$1 million mile
Slide 5: China Agreements
CHINA AGREEMENTS Key terms Intellectual Property • IP Licence Agreement – granting Partner the right to utilise CVB’s proprietary WBCT & AI technology & related know-how for the Collaboration & Term in the Territories. Licence Agreement • Regulatory Approval – CVB is responsible for seeking, obtaini
Slide 6: Q1 FY26 Purchase Orders Analysis
Q1 FY26 PURCHASE ORDERS ANALYSIS TM Discontinued • During Q1 FY26 CurveBeam AI received POs for three HiRise™ devices, and one InReach™ device. This is a growth of 33.3% over the prior corresponding period of three purchase orders in Q1 FY25. All device sales were in the USA. • Cash at the end of FY
Slide 7: Enhanced HiRise Project for Robotic Aided Surgical Systems
ENHANCED HIRISE™ PROJECT FOR ROBOTIC AIDED SURGICAL SYSTEMS • The Company is pleased with the increased engagement from the vendor of a major robotic system for validation of the enhanced HiRise™. CurveBeam AI has conducted several meetings including a system demonstration with the vendor R&D team d
Slide 8: BMD SaaS MDCT Module Update
BMD SAAS MDCT MODULE UPDATE Multidetector CT (MDCT) • Revised BMD regulatory strategy – clear the first BMD module on multidetector CT (MDCT) scanners, the primary technology used today. • This strategic shift enables earlier access to modest SaaS revenues from existing acute-care trauma settings, a
Slide 9: WBCT Competitors – Update
W B C T C O M P E T I T O R S – U P D AT E PlanMed Verity PlanMed XFI – WBCT – in development/future competition • Available today – FDA, CE, TGA • US FDA clearance announced • Partial foot, Ankle, knee • Space & height limits access in group surgeon settings • Unilateral and not natural bilateral w
Slide 10: Definitions
DEFINITIONS CurveBeam AI’s key metrics are defined and interpreted as follows: • Purchase order – a signed purchase order (PO) for a CT scanner (device). The Company considers POs to be a key metric as it reflects actual sales at any given time. • Receipts from customers – any cash consideration rec